新桥生物公布2026年上半年财务业绩,展示管线进展与战略执行亮点

美通社
Aug 20

践行公司战略:识别具备差异化优势的科学资产,高效推进研发,为患者与股东创造长期价值 任命Srishti Gupta医学博士、公共政策硕士为首席执行官,强化公司战略管理、治理能力和资本配置 推进Givastomig进入注册性III期研究,最早于2026年年底启动,并有望通过加速批准路径开展 继VIS-101取得支持其潜在同类最佳持久性的积极IIa期结果之后,公司正推进该药物于2026年下半年启动...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10